Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
Tiziana Ginex(Universitat de Barcelona), Carmen Gil(Instituto de Salud Carlos III), Victoria Castro(Consejo Superior de Investigaciones Científicas), Javier Garcı́a-Cárceles(Centro de Investigaciones Biológicas Margarita Salas), Vanesa Nozal(Centro de Investigaciones Biológicas Margarita Salas), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Inés Maestro(Centro de Investigaciones Biológicas Margarita Salas), Nuria E. Campillo(Centro de Investigaciones Biológicas Margarita Salas), Pablo Gastaminza(Centro Nacional de Biotecnología), Urtzi Garaigorta(Centro Nacional de Biotecnología)
Cited by 42
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293